Biggest News Aggregation in the World
📰 Accelerate Commercialization News

Page 2 - Accelerate Commercialization News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Accelerate Commercialization. Real-time updates on events, politics, business and more.

U.S. focus on Pfizer production could delay manufacturing of other COVID-19 vaccines, Serum Institute CEO warns

As the U.S. locks up supplies to make Pfizer's COVID-19 vaccine, Serum Institute of India and WHO are raising flags about global supply bottlenecks and raw materials shortfalls, Bloomberg reports. The supply disruption comes after the Biden administration tapped the Defense Production Act to increase deliveries of Pfizer's shot in the U.S.
United States Soumya Swaminathan Albert Bourla Adar Poonawalla University Of Oxford World Health Organization

Takeda keeps divestment spree rolling with $1.2B sale of diabetes meds to Japanese firm Teijin

Takedas latest sale brings its total divestment value up to about $12.9 billion. (Takeda) After inking a slate of geography-specific product selloffs last year, Takeda has turned back to Japan. Takeda locked up a deal to sell four Type 2 diabetes meds in Japan to local drugmaker Teijin Pharma for 133 billion Japanese yen ($1.2 billion), freeing up the company to focus on its core businesses in gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience. The move is the ...
United States Teijin Pharma Hypera Pharma Uncover Rare Disease Insights Accelerate Commercialization Improve Patient

Pfizer's Lorbrena breaks into front-line ALK lung cancer, jostling with Novartis, Roche and Takeda

Mar 4, 2021 10:54am The FDA has expanded Pfizers Lorbrena approval to include front-line ALK-positive non-small cell lung cancer. Pfizer’s Lorbrena has finally broken into front-line non-small cell lung cancer, where Novartis, Roche and Takeda are already jockeying for a niche market. The FDA expanded Lorbrena’s use into newly diagnosed patients with ALK-positive NSCLC, Pfizer said Wednesday. With that front-line nod, the agency converted Lorbrenas conditional green light for previously tre...
Novarti Zykadia Takeda Alunbrig Roche Alecensa Uncover Rare Disease Insights Accelerate Commercialization Improve Patient

Roche is gearing up to knock down an Irish plant—and it's complicated

Mar 4, 2021 11:33am Roche decided in 2015 to close four small-molecule manufacturing plants around the world. It found buyers for three. But the one that the company couldnt sell was in Clarecastle, Ireland. Destruction of the facility begins in June. (Roche) Unable to sell its plant in Clarecastle, Ireland, Roche will take a wrecking ball to the facility in June. It won’t be a simple process. In fact, a timeline of June 2021 to May 2028 has been listed for the project, which requires removi...
Baden Wuberg Clare County Council Uncover Rare Disease Insights Accelerate Commercialization Improve Patient Job Cuts

Biogen cements gene therapy ambitions with $200M factory in Research Triangle

Mar 4, 2021 11:10am Biogen plans to bring on 90 new employees to staff its planned gene therapy manufacturing facility. (Biogen) As Biogen awaits an FDA decision on its controversial Alzheimers disease hopeful aducanumab, the company is setting the stage for an entry into the hot gene therapy field.  Biogen has drawn up plans for a new gene therapy manufacturing facility at its Research Triangle Park campus in North Carolina. The 175,000-square-foot facility will be designed to scale up the...
North Carolina United States Research Triangle Park Uncover Rare Disease Insights Accelerate Commercialization Improve Patient

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Merck snares $269M in U.S. funding to prep manufacturing for Johnson & Johnson's COVID-19 vaccine

Merck's "wartime" coronavirus tie-up with Johnson & Johnson puts the vaccine giant on deck to support drug substance, formulation and vial-filling work in the U.S. And the government is chipping in with $269 million to equip two Merck manufacturing plants for the work.
United States White House District Of Columbia Alex Gorsky Eli Lilly Joe Biden

FDA slaps FibroGen, AstraZeneca with last-minute roxadustat AdCom, cuing another delay for anemia drug

Mar 3, 2021 10:50am The FDA has sent a last-minute notification of an advisory committee review of FibroGen and AstraZenecas first-in-class anemia candidate roxadustat, threatening another decision delay. (FDA) FibroGen and AstraZeneca already endured a delay in the U.S. review of their anemia candidate roxadustat. Just as the pair was expecting to snag its first-in-class approval, as the revised date draws near, a capricious FDA has stunned the companies with a second blow. The FDA will conv...
Geoffrey Porges Andrew Berens Johnson Epogen Procrit Enrique Conterno Difei Yang Uncover Rare Disease Insights

Gilead cuts jobs in California, moving some to new North Carolina business center

Gilead Sciences plans to cut more than 170 jobs in California, as it builds a new business services center in North Carolina. The Foster City-based pharma will transfer about half of the jobs to the consolidated services hub now under construction in the Research Triangle Park area.
United States Tampa Bay North Carolina Foster City Research Triangle Park San Francisco

What does it take to supply COVID-19 vaccines across the globe? Here's how the leading players are working it

Mar 3, 2021 9:45am COVID-19 vaccine shipments are now underway. Here are the supply chains tasked with producing billions of doses. (nevodka/iStock/Getty Images Plus/Getty Images) As COVID-19 gained steam worldwide last spring, little was known about the disease and the havoc it would wreak on the world. A year later, vaccines offer hope in the fight against the virus, but it will be a monumental task to produce them and deliver them around the planet. That these vaccines were invented, put th...
United States United Kingdom Czech Republic Region Flamande Grand River Mexico General

CDMO Celonic to beef up cell and gene therapy work at up-and-coming Novartis hub

Mar 3, 2021 12:19pm Novartis in February said it would convert manufacturing operations in Stein, Switzerland, into a life sciences hub focused on cell and gene therapy production. (Novartis) Like many CDMOs these days, Switzerlands Celonic aims to make a big splash in cell and gene therapy—and its picked up space at an emerging Novartis life sciences hub to take that work to the next level.  Celonic sewed up a long-term lease for production and office space in the WST-222 building of Nov...
Switzerland General Konstantin Matentzoglu Life Science Park Uncover Rare Disease Insights Accelerate Commercialization Improve Patient

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science